Dianthus Therapeutics, Inc. is a clinical stage biotechnology company focused on discovering and developing best in class therapies for patients with severe autoimmune diseases. The company’s lead product candidate, claseprubart, is a monoclonal antibody designed to selectively inhibit the active C1s component of the classical complement pathway, enabling subcutaneous administration via a prefilled pen. A second candidate, DNTH212, is a bifunctional fusion protein that targets plasmacytoid dendritic cell BDCA2 to reduce type I interferon production while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Both programs aim to address unmet needs in diseases such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and systemic lupus erythematosus.

As a company that has not yet generated product revenue, Dianthus Therapeutics generates income primarily through upfront payments, milestone payments, and potential royalties from licensing and collaboration agreements. The company has entered into agreements with Tenacia Biotechnology (Hong Kong) Co., Limited for development and commercialization rights to claseprubart in Greater China, and with Nanjing Leads Biolabs Co., Ltd. for comparable rights to DNTH212 outside Greater China. Additional arrangements include a license with Zenas BioPharma, Inc. (now held by Tenacia), and a manufacturing services agreement with WuXi Biologics (Hong Kong) Limited. These contracts provide cash payments upon achievement of preclinical, clinical and regulatory milestones, as well as royalty streams based on future net sales of any approved products.

Dianthus Therapeutics occupies a niche within the broader autoimmune therapeutics market by focusing on selective inhibition of the C1s protein, a strategy that aims to preserve the lectin and alternative complement pathways while blocking the pathogenic classical cascade. This approach differentiates the company from competitors that target downstream complement components such as C5, which carry boxed warnings for serious infections due to broad pathway inhibition. Key rivals in the generalized myasthenia gravis space include Alexion’s Soliris and Ultomiris, argenx’s Vyvgart and Vyvgart Hytrulo, and Roche’s experimental FcRn inhibitors. In chronic inflammatory demyelinating polyneuropathy, the company faces competition from immunoglobulin products, argenx’s Vyvgart Hytrulo, and Sanofi’s investigational C1s inhibitor riliprubart. The company’s advantages lie in the extended half-life of its molecules, the potential for less frequent subcutaneous dosing and a safety profile that seeks to limit infection risk.

The company intends to serve patients suffering from severe autoimmune disorders, particularly those with acetylcholine receptor-positive generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and systemic lupus erythematosus. In addition, Dianthus Therapeutics works with licensing partners such as Tenacia and Leads to bring its therapies to specific geographic territories, and relies on contract manufacturers like WuXi Biologics for clinical and commercial supply. Ultimately, the end users of its potential medicines are individuals receiving care from neurologists, immunologists and other specialty providers.